Match!
Yinghong Wang
University of Texas MD Anderson Cancer Center
CancerColitisDiabetes mellitusGeneral surgeryMedicine
120Publications
13H-index
1,511Citations
What is this?
Publications 123
Newest
#1David J. Pinato (Imperial College London)H-Index: 20
#2Takahiro Kaneko (Imperial College London)
Last. Abdul Rafeh Naqash (ECU: East Carolina University)H-Index: 5
view all 26 authors...
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI in HCC. We tested the accuracy of the albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker to the Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset of HCC patients, we assessed safety and efficacy of ICI ac...
Source
#1Anusha Shirwaikar Thomas (University of Texas MD Anderson Cancer Center)H-Index: 1
#2Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
Source
#1John B. A. G. Haanen (NKI-AVL: Netherlands Cancer Institute)H-Index: 61
#2Marc S. ErnstoffH-Index: 51
Last. Michel ObeidH-Index: 12
view all 10 authors...
Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams are hesitant to retreat in this scenario, despite the fact that a number of patients may derive clinical benefit from this approach. Balancing such clinical benefit and treatment-related toxicities for...
4 CitationsSource
#1Hamzah Abu-SbeihH-Index: 11
#2David SzafronH-Index: 1
Last. William A. RossH-Index: 28
view all 12 authors...
Source
#1Ecaterina Ileana Dumbrava (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Maria E. Suarez-Almazor (University of Texas MD Anderson Cancer Center)H-Index: 64
Last. Blake M. Warner (NIH: National Institutes of Health)H-Index: 9
view all 20 authors...
Source
#1Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
#2Weijie Ma (University of Texas MD Anderson Cancer Center)
Last. Herbert L. DuPontH-Index: 87
view all 5 authors...
Source
#1Hiba Ali (BCM: Baylor College of Medicine)H-Index: 1
#2Weijie Ma (University of Texas MD Anderson Cancer Center)
Last. Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
view all 8 authors...
Source
#1Petros Fessas (Imperial College London)H-Index: 2
#2Ahmed Omar Kaseb (University of Texas MD Anderson Cancer Center)H-Index: 30
Last. Bo Yu (Lincoln Hospital)
view all 20 authors...
Source
#1Shruti Khurana (University of Texas Health Science Center at Houston)H-Index: 1
#2Hamzah Abu-Sbeih (UMKC: University of Missouri–Kansas City)H-Index: 1
Last. Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
view all 6 authors...
Source
#1Weijie Ma (University of Texas MD Anderson Cancer Center)
#2Hamzah Abu-Sbeih (UMKC: University of Missouri–Kansas City)H-Index: 1
Last. Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 13
view all 5 authors...
Source
12345678910